Evidence map›Paper›PMID 37513791›Full record

ArticlePathogens (Basel, Switzerland)2023

Analysis of Lung Microbiome in COVID-19 Patients during Time of Hospitalization.

Linlin Xie, Liangjun Chen, Xinran Li, Junying Zhou, Hongpan Tian, Jin Zhao, Zhiqiang Li, Yirong Li

Open access · goldAbstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Fungal lung disease.The European respiratory journal · 2024
    Review
  7. A proposed approach to pulmonary long COVID: a viewpoint.The European respiratory journal · 2024
    Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Typing ofPathogens (Basel, Switzerland) · 2023
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Linlin XieDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Liangjun ChenDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Xinran LiDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Junying ZhouDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Hongpan TianDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Jin ZhaoDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Zhiqiang LiDepartment of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.ORCID 0000-0002-4148-780X
Yirong LiDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Wuhan University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

Key Project for Anti-2019 Novel Coronavirus Pneumonia from the National Key Research and Development Program of China 2020YFC0845500National Key Research and Development Program of China 2018YFE0204500National Natural Science Foundation of China 82000021
6 · The paper itself

Abstract

backgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the pathogenic agent of the rapidly spreading pneumonia called coronavirus disease 2019 (COVID-19), primarily infects the respiratory and digestive tract. Several studies have indicated the alterations of the bacterial microbiome in the lower respiratory tract during viral infection. However, both bacterial and fungal microbiota in the lung of COVID-19 patients remained to be explored.

methodsIn this study, we conducted nanopore sequencing analyses of the lower respiratory tract samples from 38 COVID-19 patients and 26 non-COVID-19 pneumonia controls. Both bacterial and fungal microbiome diversities and microbiota abundances in the lung were compared.

resultsOur results revealed significant differences in lung microbiome between COVID-19 patients and non-COVID-19 controls, which were strongly associated with SARS-CoV-2 infection and clinical status. COVID-19 patients exhibited a notably higher abundance of opportunistic pathogens, particularly

conclusionsOur study highlights the differences in lung microbiome diversity and composition between COVID-19 patients and non-COVID-19 patients. This may contribute to predicting co-pathogens and selecting optimal treatments for respiratory infections caused by SARS-CoV-2.

Indexed as

COVID-19lung microbiotananopore sequencingSARS-CoV-2

Identifiers

PMID37513791
PMCPMC10386632
OpenAlexW4384666076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.